Literature DB >> 29472358

Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.

Bernhard Gerber1, Martina Manzoni2, Valeria Spina3, Alessio Bruscaggin3, Marta Lionetti2, Sonia Fabris4, Marzia Barbieri4, Gabriella Ciceri2, Alessandra Pompa4, Gabriela Forestieri3, Erika Lerch5, Paolo Servida5, Francesco Bertoni3, Emanuele Zucca5, Michele Ghielmini5, Agostino Cortelezzi2,4, Franco Cavalli3,5, Georg Stussi1, Luca Baldini2,4, Davide Rossi6,3, Antonino Neri7,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29472358      PMCID: PMC6058782          DOI: 10.3324/haematol.2017.184358

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.

Authors:  S Mithraprabhu; T Khong; M Ramachandran; A Chow; D Klarica; L Mai; S Walsh; D Broemeling; A Marziali; M Wiggin; J Hocking; A Kalff; B Durie; A Spencer
Journal:  Leukemia       Date:  2016-11-30       Impact factor: 11.528

Review 2.  Liquid biopsies: genotyping circulating tumor DNA.

Authors:  Luis A Diaz; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

Review 3.  Liquid biopsy: monitoring cancer-genetics in the blood.

Authors:  Emily Crowley; Federica Di Nicolantonio; Fotios Loupakis; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2013-07-09       Impact factor: 66.675

4.  Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.

Authors:  K M Kortuem; E Braggio; L Bruins; S Barrio; C S Shi; Y X Zhu; R Tibes; D Viswanatha; P Votruba; G Ahmann; R Fonseca; P Jedlowski; I Schlam; S Kumar; P L Bergsagel; A K Stewart
Journal:  Blood Cancer J       Date:  2016-02-26       Impact factor: 11.037

5.  Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Authors:  Even Holth Rustad; Eivind Coward; Emilie R Skytøen; Kristine Misund; Toril Holien; Therese Standal; Magne Børset; Vidar Beisvag; Ola Myklebost; Leonardo A Meza-Zepeda; Hong Yan Dai; Anders Sundan; Anders Waage
Journal:  Haematologica       Date:  2017-04-06       Impact factor: 9.941

6.  Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.

Authors:  Anna Oberle; Anna Brandt; Minna Voigtlaender; Benjamin Thiele; Janina Radloff; Anita Schulenkorf; Malik Alawi; Nuray Akyüz; Manuela März; Christopher T Ford; Artus Krohn-Grimberghe; Mascha Binder
Journal:  Haematologica       Date:  2017-02-09       Impact factor: 9.941

7.  Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.

Authors:  Olena Kis; Rayan Kaedbey; Signy Chow; Arnavaz Danesh; Mark Dowar; Tiantian Li; Zhihua Li; Jessica Liu; Mark Mansour; Esther Masih-Khan; Tong Zhang; Scott V Bratman; Amit M Oza; Suzanne Kamel-Reid; Suzanne Trudel; Trevor J Pugh
Journal:  Nat Commun       Date:  2017-05-11       Impact factor: 14.919

8.  Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Authors:  Christopher Abbosh; Nicolai J Birkbak; Gareth A Wilson; Mariam Jamal-Hanjani; Tudor Constantin; Raheleh Salari; John Le Quesne; David A Moore; Selvaraju Veeriah; Rachel Rosenthal; Teresa Marafioti; Eser Kirkizlar; Thomas B K Watkins; Nicholas McGranahan; Sophia Ward; Luke Martinson; Joan Riley; Francesco Fraioli; Maise Al Bakir; Eva Grönroos; Francisco Zambrana; Raymondo Endozo; Wenya Linda Bi; Fiona M Fennessy; Nicole Sponer; Diana Johnson; Joanne Laycock; Seema Shafi; Justyna Czyzewska-Khan; Andrew Rowan; Tim Chambers; Nik Matthews; Samra Turajlic; Crispin Hiley; Siow Ming Lee; Martin D Forster; Tanya Ahmad; Mary Falzon; Elaine Borg; David Lawrence; Martin Hayward; Shyam Kolvekar; Nikolaos Panagiotopoulos; Sam M Janes; Ricky Thakrar; Asia Ahmed; Fiona Blackhall; Yvonne Summers; Dina Hafez; Ashwini Naik; Apratim Ganguly; Stephanie Kareht; Rajesh Shah; Leena Joseph; Anne Marie Quinn; Phil A Crosbie; Babu Naidu; Gary Middleton; Gerald Langman; Simon Trotter; Marianne Nicolson; Hardy Remmen; Keith Kerr; Mahendran Chetty; Lesley Gomersall; Dean A Fennell; Apostolos Nakas; Sridhar Rathinam; Girija Anand; Sajid Khan; Peter Russell; Veni Ezhil; Babikir Ismail; Melanie Irvin-Sellers; Vineet Prakash; Jason F Lester; Malgorzata Kornaszewska; Richard Attanoos; Haydn Adams; Helen Davies; Dahmane Oukrif; Ayse U Akarca; John A Hartley; Helen L Lowe; Sara Lock; Natasha Iles; Harriet Bell; Yenting Ngai; Greg Elgar; Zoltan Szallasi; Roland F Schwarz; Javier Herrero; Aengus Stewart; Sergio A Quezada; Karl S Peggs; Peter Van Loo; Caroline Dive; C Jimmy Lin; Matthew Rabinowitz; Hugo J W L Aerts; Allan Hackshaw; Jacqui A Shaw; Bernhard G Zimmermann; Charles Swanton
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

9.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

10.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

View more
  14 in total

Review 1.  Tracking myeloma tumor DNA in peripheral blood.

Authors:  Johannes M Waldschmidt; Tushara Vijaykumar; Birgit Knoechel; Jens G Lohr
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-14       Impact factor: 3.020

2.  A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.

Authors:  Stefania Oliva; Lorenzo De Paoli; Marina Ruggeri; Simona Caltagirone; Rossella Troia; Daniela Oddolo; Mattia D'Agostino; Milena Gilestro; Roberto Mina; Elona Saraci; Gloria Margiotta Casaluci; Elisa Genuardi; Sara Bringhen; Mario Boccadoro; Paola Omedé
Journal:  Ann Hematol       Date:  2021-01-03       Impact factor: 3.673

3.  Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.

Authors:  David Vrabel; Lenka Sedlarikova; Lenka Besse; Lucie Rihova; Renata Bezdekova; Martina Almasi; Veronika Kubaczkova; Lucie Brožová; Jiri Jarkovsky; Hana Plonkova; Tomas Jelinek; Viera Sandecka; Martin Stork; Ludek Pour; Sabina Sevcikova; Roman Hajek
Journal:  Eur J Haematol       Date:  2019-12-20       Impact factor: 2.997

4.  Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma.

Authors:  Martina Manzoni; Valentina Marchica; Paola Storti; Bachisio Ziccheddu; Gabriella Sammarelli; Giannalisa Todaro; Francesca Pelizzoni; Simone Salerio; Laura Notarfranchi; Alessandra Pompa; Luca Baldini; Niccolò Bolli; Antonino Neri; Nicola Giuliani; Marta Lionetti
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

Review 5.  A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity.

Authors:  Matteo C Da Vià; Bachisio Ziccheddu; Akihiro Maeda; Filippo Bagnoli; Giulia Perrone; Niccolò Bolli
Journal:  Hemasphere       Date:  2020-11-24

6.  Clinical Significance of Circulating Cell-Free DNA Detection in Multiple Myeloma: A Meta-Analysis.

Authors:  Xueshi Ye; Wanli Li; Lifei Zhang; Junyao Yu
Journal:  Front Oncol       Date:  2022-02-18       Impact factor: 6.244

7.  High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma.

Authors:  Soushi Ibata; Masayoshi Kobune; Shohei Kikuchi; Masahiro Yoshida; Shogo Miura; Hiroto Horiguchi; Kazuyuki Murase; Satoshi Iyama; Kohichi Takada; Koji Miyanishi; Junji Kato
Journal:  Oncotarget       Date:  2018-05-18

Review 8.  Potential Clinical Application of Genomics in Multiple Myeloma.

Authors:  Cinnie Yentia Soekojo; Sanjay de Mel; Melissa Ooi; Benedict Yan; Wee Joo Chng
Journal:  Int J Mol Sci       Date:  2018-06-10       Impact factor: 5.923

Review 9.  Liquid biopsies for multiple myeloma in a time of precision medicine.

Authors:  Bruna Ferreira; Joana Caetano; Filipa Barahona; Raquel Lopes; Emilie Carneiro; Bruno Costa-Silva; Cristina João
Journal:  J Mol Med (Berl)       Date:  2020-04-04       Impact factor: 4.599

10.  Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora's Box of Multiple Myeloma.

Authors:  Juan-José Garcés; Jesús San-Miguel; Bruno Paiva
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.